Shares in Value Logo
Product Review Img Vertical

Date : 19/12/2023

Analysing Volpara Health Technologies Ltd (ASX: VHT)

Volpara Health Technologies Ltd (ASX: VHT), a key player in the healthcare software industry, has recently become a focal point in the financial markets. The company, known for its innovative breast screening analysis technology, has seen its share price skyrocket, reaching a 52-week high. This surge is primarily due to a takeover agreement, which has piqued the interest of investors and market analysts. In this article, we will explore the nuances of this development and its implications for the future of Volpara and its shareholders.

Volpara Stock Overview

The sudden upsurge in Volpara’s stock is noteworthy. VHT has escalated to $1.09, marking a staggering 43% increase. This significant growth has not only brought Volpara into the limelight but also sparked curiosity about the underlying factors driving this trend.

asx vht shares analysis

Why is Volpara’s ASX Healthcare Stock Soaring?

Volpara stock, a company specializing in health imaging technology, has seen a significant surge in investor interest today. This surge is due to the company’s announcement of receiving and agreeing to a takeover proposal.

As per the latest information, Volpara has finalized an arrangement with Lunit Inc., where Lunit will purchase all shares of Volpara at $1.15 each in cash. This offer is notably generous, offering a 48% premium compared to the most recent trading value of the shares, putting the company’s worth at approximately $295.7 million. However, this development might be a source of discontent for those who have held Volpara shares since 2019 or 2020, when the stock prices reached as high as $2.00 and $1.70, respectively.

The management team at Volpara views this deal as beneficial financially and for broader humanitarian reasons. They anticipate that this acquisition will expedite Volpara’s mission to combat cancer. Additionally, the merger will enrich Volpara’s vast image database of over 100 million pictures with Lunit’s advanced AI capabilities and medical expertise, enhancing its technological edge in the field.

Is the Deal Set in Stone?

Despite the excitement, the takeover still needs to be a done deal. Several approvals are still required, including those from Volpara’s shareholders, the Court, and the New Zealand Overseas Investment Office. Nevertheless, the likelihood of the deal’s approval is high, with key shareholders like Harbour Asset Management, non-executive director Roger Allen, and Volpara founder Ralph Highnam, who collectively hold 25.92% of Volpara shares, indicating their support for the takeover.

Management Remarks

Volpara’s Chairman, Paul Reid, has voiced strong support for the acquisition. He views the scheme as providing shareholders with substantial, risk-adjusted value and certainty. The management believes that this transaction will accelerate Volpara’s mission of saving families from cancer and enhance its technological capabilities, especially with the support of Lunit’s in-house radiologists and complementary technologies.

Conclusion

Such a takeover bid appears attractive to the shareholders; however, it raises questions about why the company failed to unveil or exploit its latent abilities until now. The high price is very expensive, given that Volpara has recently embarked on a path towards positive cash flow profitability. On the other hand, agreeing to such an offer may prevent the company from being completely independent on ASX. However, this transaction will certainly come under scrutiny as shareholders look forward to what Volpara has up its sleeves with regard to cutting-edge innovations in the healthcare market.

Are You Looking To Buy The Best Stocks In 2024?

Stay on top of upcoming market trends! Whether you are an SMSF investor or a young investor with your portfolio, we cover a wide range of stocks across all sectors, including mining, financials, industrials, real estate, technology, health and biotech, etc. It will give you an edge to invest and trade ASX listed stocks across large, mid and small caps with an advantage.

Get stock tips with our Market Experts. We help self-directed investors and self-managed super funds (SMSF) make smarter investment decisions and get better returns. Fill in your details and download your free Report instantly for Top 3 Dividend Stocks to buy in 2024!

 

Top 5 ASX Stocks
to Buy for Capital Growth in 2024

Shares In Value - Top 5 ASX Stocks to Buy - Cover 2024
The hardest part to finding growth stocks is having an ability to understand the finer details of these companies from their valuations through to first mover advantage and having key factors on hand to make informed investment decisions.

Our experts take the guesswork out.
ASX insight Stocks Landing

Download Your Free Report

By downloading this report, you agree to our terms and conditions and privacy policy

Scroll to Top

Login

By submitting this form, I agree to the TERMS AND CONDITIONS and PRIVATE POLICY

Income Stocks - Blogs

Please fill in your details to download the free dividend shares report.

By downloading this report, you agree to our terms and conditions and privacy policy

Just 10 Seconds Away From Your Free Report!
Income Stocks - Popup Blog

Please fill in your details to download the free dividend shares report.

By clicking 'Download Report', I accept the Privacy Policy and Member Terms & Conditions.

We will send your report instantly. Please put your correct email address and phone number.